newsfilter
← Latest News
Business Wire·

Arena Pharmaceuticals Achieves Target Enrollment for Etrasimod CULTIVATE Study A

- Evaluating 2 mg and 3 mg etrasimod in study participants with moderate to severe Crohn's Disease (CD) - Topline data from CULTIVATE Study A on track for Q2 2022 Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) today announced that it has achieved targe